Humacyte (HUMA) vs Protara Therapeutics (TARA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Humacyte (HUMA) has outperformed Protara Therapeutics (TARA) over the past year, losing 63.5% versus a loss of 68.6%. Over five years, TARA leads with a -67.8% price change compared with -95.9% for HUMA. Protara Therapeutics is the larger company by market cap ($140.4 million vs $123.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HUMA | TARA |
|---|---|---|
| Share price | $0.4454 | $2.28 |
| Market cap | $123.73M | $140.38M |
| 1-day change | -17.90% | -5.00% |
| YTD return | -53.65% | -57.22% |
| 1-year return | -63.49% | -68.60% |
| 5-year return | -95.94% | -67.80% |
| EPS (TTM) | $-0.45 | $-1.39 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $2.04M | — |
| Net income (latest FY) | $-40.83M | $-57.44M |
| Gross margin | -376.05% | — |
| Operating margin | -5306.04% | — |
| Net margin | -2003.58% | — |
| 52-week high | $1.53 | $7.82 |
| 52-week low | $0.337 | $2.09 |
| Distance from 52-week high | -70.79% | -70.84% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +268.21% | +1010.96% |
| Average volume | 5.36M | 1.07M |
| Shares outstanding | 277.80M | 61.57M |
| Employees | 184 | 46 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Humacyte
HUMA stock →Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 184 employees
About Protara Therapeutics
TARA stock →Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 46 employees
HUMA vs TARA FAQ
Which is bigger, Humacyte or Protara Therapeutics?
Protara Therapeutics (TARA) is larger, with a market capitalization of $140.38M compared with $123.73M for Humacyte (HUMA).
Which stock has performed better over the past year, HUMA or TARA?
HUMA returned -63.49% over the past 12 months, compared with -68.60% for TARA (price return, excluding dividends). Past performance does not predict future results.
Are Humacyte and Protara Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.